Skip to main content
Main menu
Home
About
About the Journal
Editorial Board
Role of Associate & Senior Editors
Board Disclosures
Supplemental Issues
Advertising
Subscribe
Recommend JAD
Related Links
Related IOS Press Journals
Upcoming Meetings
Contact
News
Submit
For Authors
Submission Guidelines
Submission Letter and Manuscript Transmission
Manuscript Preparation
Submission Checklist
Copyright
Permissions
Review Process
Publication Fee / Open Access Option
Proofs/Reprints
Policies
Financial Disclosure
Open Access Mandates
Preprints/Preprint Servers
Policy on Use of Human Subjects
Policy on Animal Use
Policy on Ethics
Contents
Current Issue
All Issues (including upcoming)
Articles in Pre-Press
Books
Letters to the Editor
Blog
Members
Rankings/Awards
Journal of Alzheimer's Disease Reports
Main menu
Home
About
News
Submit
Contents
Blog
Members
Rankings/Awards
Journal of Alzheimer's Disease Reports
Home
About
About the Journal
Editorial Board
Role of Associate & Senior Editors
Board Disclosures
Supplemental Issues
Advertising
Subscribe
Recommend JAD
Related Links
Related IOS Press Journals
Upcoming Meetings
Contact
News
Submit
For Authors
Submission Guidelines
Submission Letter and Manuscript Transmission
Manuscript Preparation
Submission Checklist
Copyright
Permissions
Review Process
Information For Reviewers
Role of Associate & Senior Editors
Publication Fee / Open Access Option
Payment Form
Proofs/Reprints
Pre-Press/Proofs
Reprints
Policies
Financial Disclosure
Open Access Mandates
Preprints/Preprint Servers
Policy on Use of Human Subjects
Policy on Animal Use
Policy on Ethics
Contents
Current Issue
All Issues (including upcoming)
Articles in Pre-Press
Books
Letters to the Editor
Blog
Blog Guidelines
Members
Rankings/Awards
Alzheimer Award
Top 100
Top 100 Most Cited AD Investigators
Top 100 Most Prolific AD Investigators
The Article
Top 50 Results
Journal of Alzheimer's Disease Reports
Contents
Homepage
You are here
Home
Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer’s Disease
Manuscript Number:
16-0165R1
Author(s):
Gary W. Arendash
Disclosures
Gary W. Arendash
Equity:
1,692,000 common shares of stock in NeuroEM Therapeutics, Inc.
